Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT04326283 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated as it is considered that necessary data have been collected

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: Trametinib (0.5 mg)
DRUG: Trametinib (1 mg)
DRUG: Riluzole (100 mg)

Sponsor

Genuv Inc.